Study Design
This single-center, nonrandomized, prospective cohort study, approved by the local Ethics Committee (EC number, 04-067-0604), evaluated the association of the ratio of ApoA-II/B, compared to other established lipid-risk parameters, with postoperative mortality of 327 consecutive patients undergoing carotid surgery for ICAS from 2003 to 2012, median observation period of 102.3 months (8.5 years). The primary study outcome was death from any cause (overall death).
Sample Handling and Laboratory Measurements
Blood was drawn 0 to 7 days before carotid surgery. Lipoproteins were separated using a combined ultracentrifugation-precipitation method (β-quantification). 10 The levels of total cholesterol and triglycerides were measured using enzymatic reagents (Wako Chemicals, Neuss, Germany). Lipids and apolipoproteins (A-I, A-II, and B) were determined by immunoturbidimetry (Greiner, Flacht, Germany). Lipoprotein analyses were performed on an Olympus AU640 (Olympus Diagnostika, Hamburg, Germany).
Statistical Analysis
Quantitative associations of apo-, lipoproteins, and ratios with the primary outcome (overall mortality) were estimated in multivariable proportional hazard models (Cox regression). Prognostic indices (PI) 11 with or without inclusion of the ApoA-I/B or ApoA-II/B ratio were compared with regard to general performance (R 2 ), calibration (X 2 , Hosmer-Lemeshow test), discrimination, and reclassification. 12 A 2-sided P value of <0.05 was considered to indicate statistical significance.
Results

Lipoprotein-Associated Hazard
Demographs, baseline concentrations, and main outcomes of 327 patients are presented in Table I Tables 1 and 2 , and cardio-, cerebro-, and vascular survival (hazard ratio, 0.62 per SD; confidence interval, 0.28-0.90; P=0.012). Pairwise comparison with ApoA-II/B in univariable and multivariable proportional hazard models predicting overall survival rendered all other parameters, including LDL/ high-density lipoprotein and ApoA-I/B, insignificant (P>0.05). Moreover, ApoA-II/B showed the highest stratification, illustrated in Figure I in the online-only Data Supplement.
Prognostic Value of ApoA-II/B
To estimate the usefulness of ApoA-II/B as a prognostic marker, PI based on established major cardiovascular risk factors, including history of symptomatic ICAS and lipid risk parameters (LDL; triglycerides) with (PI incl ApoAII/B ) or without (PI established ), the ratio of ApoA-II/B, were computed. The PI incl ApoAII/B showed a better general performance (Cox-Snell, R Table II in the Data Supplement, and also of 12 of 88 patients with low LDL (<100 mg/dL; 3.6%; net reclassification improvement, 0.270; P=0.041 and integrated discrimination improvement, 0.061; P=0.002), presented in Table III in the online-only Data Supplement.
Discussion
In 2013, Wang et al 7 reported significantly reduced atherosclerotic lesions in the aorta and coronary arteries of transgenic animals expressing, for the first time, human dimeric ApoA-II. Likewise, ApoB is the major apolipoprotein of LDL, but it is also present in intermediate-density lipoproteins and very lowdensity lipoprotein cholesterol, which makes its measurement a more accurate estimate of the total concentration of atherogenic particles and, thus, superior in cardiovascular risk prediction. 9 Therefore, in this study, we investigated the ratio of ApoA-II/B, which emerged as a better predictor of lipoprotein-associated risk of cardiovascular and overall mortality compared with all 
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other established lipoprotein parameters, including ApoA-I, ApoA-II, or ApoA-I/B in patients undergoing carotid endarterectomy for ICAS. Moreover, its inclusion in a prognostic model based on major cardiovascular risk factors 13 and established lipoprotein risk factors allowed a significant improvement of prediction of postoperative overall mortality, also in patients at lower lipid risk, ie, with LDL serum concentrations of <100 mg/dL. Consequently, this ratio may provide an efficient treatment target for actual lipid-lowering therapies.
Limitations
Eventual changes in patients' dietary habits, which might bias this study's findings, have not been documented.
Conclusions
This study identifies the ratio of apolipoprotein A-II/B as the best prognostic parameter for lipoprotein-associated risk of postoperative overall mortality compared with other established lipid parameters in patients undergoing carotid surgery for high-grade ICAS. This suggests that this ratio might provide an efficient diagnostic tool and treatment target of actual lipid-lowering therapies, which is supported by its retained predictive value within a low-LDL range. 
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Materials and Methods
Study Design
This study was a single-center, non-randomized, prospective case series evaluating the effect of apolipoprotein A-II baseline concentrations and associated lipoprotein ratios on postoperative survival in a vascular high-risk population. All patients provided written informed consent. The study was approved by the Viennese Ethics Committee (EC nr: 04-067-0604) and extended annually upon written request. The study was designed to enroll 300 consecutive patients with a continuous follow-up to allow detection of a significant difference between low and high lipoprotein concentrations in the risk of the primary outcome. (Table 1) . No patient was lost during follow up. Patients who gave their written informed consent underwent a standardized vascular screening. Exclusion criteria comprised age 18 years or younger, a previous ipsilateral carotid endarterectomy (CEA), any major life-threatening condition other than carotid stenosis. At discharge from the hospital each patient received best medical treatment and a note was sent to the patient's physician.
Study Population
From 2003 January to 2004 April, 327 consecutive patients (124 female, 203 male) undergoing carotid surgery for high-grade stenosis of their internal carotid artery were recruited, who completed the study until January 1 st , 2012
Measurement of cardiovascular risk factors
During vascular screening, all patients underwent a physical examination with documentation of all risk factors. Blood pressure measurements were made on the left arm of the seated patient. Hypertension was defined as 2 measurements of systolic blood pressure above 140 mmHg or use of antihypertensive medication. Cigarette smoking status was ascertained by self-report. Diabetes was defined as fasting glucose above 120 mg/dL or use of insulin or other pharmacotherapy for glycemic control.
Sample handling and laboratory measurements
Blood was drawn from fasting individuals by venipuncture of the antecubital vein and collected in standard K3-EDTA tubes (Vacuette EDTA Tubes, Greiner Bio-One, Kremsmünster, Austria) 0-7 days prior to carotid surgery during preoperative evaluation in the department's outpatient clinic. Blood samples were centrifuged (10 minutes at 2000 G) and plasma was decanted within 15 minutes after sampling and stored at minus 80 °C until analysis.
Determination of Lipids and Apolipoproteins
Lipoproteins were separated using a combined ultracentrifugation-precipitation method (β-quantification) 1 . The levels of total cholesterol and triglycerides were measured using enzymatic reagents (Wako Chemicals, Neuss, Germany). Lipids and Apolipoproteins (A-I, A-II, B) were determined by immunoturbidimetry (Greiner, Flacht, Germany). Lipoprotein analyses were performed on an Olympus AU640 (Olympus Diagnostika, Hamburg, Germany). Lipid and apolipoprotein measurements had between day coefficients of variation of < 5%.
Follow-up
Patients were monitored regularly for the occurrence of the primary outcome. Follow up of patients was at 1, 3, 6 and 12 months postoperatively and on an annual basis thereafter. In case patients missed their appointment for the annual control visit, phone calls were made. Data of deceased patients were crosschecked with the Austrian public death registry with January the 1 st , 2012 as census date.
Outcome events
The primary study outcome was death from any cause (overall death) within the median observation period of 102.3 months (8.5 years) after CEA. All primary outcomes were obtained by written diagnostic reports of independent doctors or pathologists from clinical or pathological departments or corresponding hospital registries, wherever patients deceased. These documents (patient charts, death certificates, etc.) were accessed through the Viennese hospital online databank. Additionally, all primary outcomes were crosschecked with the Austrian public death registry provided by Statistics Austria 2 , an independent governmental organization for performing scientific services in the area of federal statistics. No study author was involved in the determination of death cause. Deaths classified as from cardio-, cerebro-or vascular causes were from myocardial infarction or stroke, congestive heart failure, arrhythmia, mesenterial thrombosis, or ruptured arterial or aortic aneurysm without clinical or postmortem evidence of another cause. Deaths from uncertain causes were referred to as non-vascular deaths, and not assumed to be of cardiovascular origin. Cancers were classified according to the International Classification of Diseases, 10 th Revision (ICD-10). Transient ischemic attack (TIA) was defined as a focal neurologic deficit lasting less than 24 hours, stroke lasting more than 24 hours. All cerebral adverse events were documented by cranial CT or MRI.
Statistical Analysis
The observation period lasted from the date of first sample retrieval (2003 Jan -April 2004) until the census date (Jan 1 st , 2012; median observation period 102.3 months). All 327 patients (126 female, 201 male) were observed until the census date or for the primary outcome event, whatever occurred first. Lipid and apolipoprotein baseline concentrations showed a normal statistical distribution. Apo-and lipoprotein ratios were computed for each patient, yielding a ratio of LDL/HDL cholesterol and apolipoprotein AI/B and A-II/B.
The risk of occurrence of the primary outcome was estimated by survival estimates of percentile groups (tertiles) of apo-, lipoprotein baseline concentrations (Kaplan Meier Curves, log-rank test). The quantitative association of apo-and lipoproteins and ratios with the primary outcome was calculated in proportional hazard models (Cox Regression) adjusted for major cardiovascular risk factors (CVRF: Sex, Age at sample retrieval/surgery, Body Mass Index (BMI), Hypertension, Smoker, clinical presentation with symptomatic Internal Carotid Artery Stenosis (History of symptomatic ICAS), Diabetes mellitus, Creatinine) to estimate hazard ratios (HR; 95% confidence interval CI) for the occurrence of the primary endpoint. Separate analyses included baseline use of statins, too (data not shown). Pairwise comparison of all lipids, apolipoproteins and associated ratios was performed in uni-and multivariable proportional hazard models, using backward elimination removing nonsignificant variables.
Prognostic indices (PI) are linear predictor scores which represent the sum of the product of mean-centered covariate values and their corresponding parameter estimates for each case 3 . PIs for overall survival (primary endpoint) were computed based on aforementioned major CVRFs plus triglycerides (TG), total Cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) with or without inclusion of the ApoA-I/B, ApoA-II/B ratio. PIs were compared with regards to general performance (R 2 ), calibration (X 2 , Hosmer-Lemeshow test) and discrimination (Area-under-the Receiver Operating Characteristic ROCCurve) 4, 5 . Reclassification of patients was assessed by quintiles of prognostic indices, estimating Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) 5 . A two-sided P value (P) of less than 0.05 was considered to indicate statistical significance. All analyses were performed with the use of SPSS 20 (IBM Inc., Somers, NY 10589, USA.).
Supplemental Tables
Supplemental Table I . Baseline Characteristics and Outcomes of patients (n=327) undergoing carotid surgery for high-grade internal carotid artery stenosis (ICAS). Total n = number of patients at risk, n of events = number of patients with primary outcome, T = tertiles of, n censored = patients surviving until census date. P value by the log-rank test
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